RESEARCH
KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRCA pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic colorectal cancer. (Clinical Colorectal Cancer)